|
R.Sh. Abdulaeva, D.A. Gavrilova, G.G. Makiev, E.S. Obarevich, E.G. Gromova, N.S. Besova, A.A. Tryakin, D.P. Guzhavin
Chemotherapy in patients with advanced gastrointestinal tumors and end-stage chronic kidney disease. Brief literature review and clinical case reports
|
№7 / 2024
|
|
Ya.A. Yakimenko, V.V. Kutukov, S.P. Gavrilova, K.N. Rotar
A rare clinical case: treatment of a mediastinal tumor without organospecificity
|
№7 / 2024
|
|
A.A. Salimova, M.V. Makarova, N.S. Besova, Yu.P. Kuvshinov, I.A. Karasev
Potentials for endoscopic and magnetic resonance diagnostic methods in assessing the radicality of chemoradiotherapy in patients with rectal cancer
|
№7 / 2024
|
|
Z.T. Astakhova, M.T. Zaseeva
Cardiotoxicity and chronic heart failure in the treatment of patients with gastric cancer: pathogenesis, methods of prevention and therapy
|
№7 / 2024
|
|
Chubykina S.V., Tatarinova M.Yu., Avakyan G.G., Knyazev R.I.
Neurophysiological manifestations of neuropathy induced by taxane and platinum chemotherapeutic agents
|
№6 / 2024
|
|
N.S. Besova, E.S. Obarevich, A.A. Tryakin, D.A. Gavrilova, S.N. Nered, A.E. Kalinin, I.S. Stilidi
Conversion therapy for disseminated gastric cancer. Interim results of a retrospective analysis of our own data
|
№11 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, S.S. Ereshchenko, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Analysis of the effectiveness of various neoadjuvant chemotherapy regimens in patients with T1-3N1-3M0 I–IIIC stage locally advanced breast cancer
|
№6-7 / 2023
|
|
R.S. Pesotsky, V.F. Semiglazov, P.V. Krivorotko, T.T. Tabagua, K.Yu. Zernov, A.S. Emelyanov, T.Yu. Semiglazova, N. Amirov, V.V. Mortada, D.G. Ulrikh, V.E. Levchenko, K.Yu. Rychagov, K.Yu. Zirov, V.N. Evseev
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
|
№6-7 / 2023
|
|
Ya.A. Yakimenko, V.V. Kutukov, V.V. Antonyan, M.A. Gaziev
Gastrointestinal toxicity during therapy with 5-fluorouracil
|
№6-7 / 2023
|
|
N.S. Besova
Conversion therapy for stage IV gastric cancer: a review of prognostic factors and patient selection criteria according to the literature data
|
№6-7 / 2023
|
|
V.F. Semiglazov, P.V. Krivorotko, T.Yu. Semiglazova, A.V. Komyakhov, T.T. Tabagua, M.D. Kazantseva, E.K. Zhiltsova, D.G. Ulrikh, M.V. Chervyak, A.P. Tergoeva, V.V. Klimenko, V.V. Semiglazov
Ixabepilone in the treatment of breast cancer
|
№11-12 / 2022
|
|
I.V. Poddubnaya, N.A. Ognerubov, T.S. Antipova
Thymus hyperplasia after lymphoma drug therapy: the role of PET/CT
|
№7 / 2022
|
Русский
